ENTX · Entera Bio Ltd.

Entera Bio’s Q1 2026 results reflect a deliberate ramp-up in R&D investment ($2.3M, up 101% YoY) to advance its lead oral peptide candidates—particularly EB613, whose streamlined Phase 3 protocol was submitted to the FDA in March 2026 with a primary endpoint of total hip BMD change at 12 months. The company completed a critical Phase 1 bridging study confirming bioequivalence of its single-tablet EB613 formulation versus subcutaneous Forteo®, enabling advancement into pivotal development without reformulation delays. Concurrently, the expanded 50/50 collaboration with OPKO for EB612 de-risks early clinical execution and aligns funding through Phase 1, supporting an anticipated late-2026 IND filing. Financially, the $20.4M cash position as of May 8, 2026—including $7.8M restricted for OPKO-related activities—provides runway through Q1 2027, explicitly covering EB613 Phase 3 preparation. Management commentary underscores capital efficiency: all milestones were executed by a lean core team, and the KOL webinar with leading endocrinologists reinforced strong unmet need for an oral anabolic in osteoporosis—a key commercial validation point. While net loss widened to $3.5M (vs. $2.6M YoY), the increase is fully attributable to targeted, program-specific R&D acceleration—not operational inefficiency—and aligns with Entera’s stated strategy of prioritizing high-value clinical inflection points over cost containment. The appointment of Geno Germano as Chairman further signals maturation, adding deep global pharma commercialization expertise to guide late-stage development and potential partnering decisions.